HC Wainwright Reiterates “Buy” Rating for UroGen Pharma (NASDAQ:URGN)

UroGen Pharma (NASDAQ:URGNGet Free Report)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research report issued on Tuesday, Benzinga reports. They presently have a $54.00 price objective on the stock. HC Wainwright’s price objective indicates a potential upside of 313.16% from the stock’s current price.

Separately, Oppenheimer lowered their price objective on UroGen Pharma from $35.00 to $34.00 and set an “outperform” rating for the company in a research report on Friday, March 15th.

View Our Latest Stock Report on URGN

UroGen Pharma Stock Performance

Shares of URGN stock opened at $13.07 on Tuesday. The stock has a market capitalization of $306.54 million, a P/E ratio of -3.50 and a beta of 1.09. UroGen Pharma has a fifty-two week low of $8.69 and a fifty-two week high of $24.13. The company has a 50 day moving average price of $14.81 and a 200 day moving average price of $14.75.

UroGen Pharma (NASDAQ:URGNGet Free Report) last posted its quarterly earnings data on Thursday, March 14th. The company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.05). The firm had revenue of $23.53 million during the quarter, compared to analyst estimates of $22.30 million. On average, research analysts forecast that UroGen Pharma will post -3.59 EPS for the current fiscal year.

Insider Activity at UroGen Pharma

In other UroGen Pharma news, insider Mark Schoenberg sold 12,000 shares of UroGen Pharma stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $14.05, for a total transaction of $168,600.00. Following the completion of the sale, the insider now directly owns 139,437 shares of the company’s stock, valued at approximately $1,959,089.85. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 11.13% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of URGN. RA Capital Management L.P. purchased a new position in shares of UroGen Pharma during the third quarter worth about $20,787,000. RTW Investments LP raised its holdings in shares of UroGen Pharma by 101.4% in the fourth quarter. RTW Investments LP now owns 1,726,808 shares of the company’s stock valued at $25,902,000 after buying an additional 869,344 shares during the last quarter. Silverarc Capital Management LLC acquired a new stake in shares of UroGen Pharma during the third quarter worth about $7,129,000. Superstring Capital Management LP purchased a new position in shares of UroGen Pharma during the fourth quarter worth about $3,831,000. Finally, EAM Investors LLC acquired a new position in shares of UroGen Pharma in the third quarter valued at approximately $2,389,000. 91.29% of the stock is owned by hedge funds and other institutional investors.

About UroGen Pharma

(Get Free Report)

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.

Featured Stories

Receive News & Ratings for UroGen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UroGen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.